Rituximab: Difference between revisions

Revision as of 20:58, 6 April 2010

Citable Version ^[?]

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

In medicine, rituximab is a medication that is "a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma."^[1]

The most up-to-date information about Rituximab and other drugs can be found at the following sites.

Rituximab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
Rituximab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
Rituximab - Detailed information from DrugBank.

@@ Line 1: / Line 1: @@
 {{subpages}}
-In [[medicine]], [[rituximab]] is a [[medication]] that is "a genetically engineered anti-CD20 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 Entrez protein]) [[antibody]] for the treatment of B-cell [[lymphoma]]."<ref>{{MeSH}}</ref>
+In [[medicine]], [[rituximab]] is a [[medication]] that is "a genetically engineered anti-[[CD20 antigen|CD20]] [[antibody]] for the treatment of B-cell [[lymphoma]]."<ref>{{MeSH}}</ref>
 ==References==